Abstract
Objectives To design and evaluate a novel automated glaucoma classifier from retinal fundus images.
Methods We designed a novel Artificial Intelligence (AI) automated tool to detect glaucoma from retinal fundus images. We then downloaded publicly available retinal fundus image datasets containing healthy patients and images with verified glaucoma labels. Two thirds of the images were used to train the classifier. The remaining third of the images was used to create several cross-validation evaluation sets with a realistic glaucoma prevalence, to evaluate the classifier’s performance in a screening scenario.
Results 10,658 retinal fundus images from seven different sources were found and downloaded. They were randomly divided into 7,106 for training and 3,551 for validation. Glaucoma prevalence was 24%. Using the validation set, we created 50 random sets of 1,000 images with a 5% glaucoma prevalence. On these sets, the classifier reached a detection rate of 84.1% (CI 95=+-1.1%) and 95.8% (CI 95=+-0.2%) specificity.
Conclusions A novel glaucoma classifier from retinal fundus images showed promising results as screening tool on a large cohort of patients. A large clinical study is needed to confirm these results.
Competing Interest Statement
All authors are Transmural Biotech employees
Clinical Trial
This is an online study performed on publicly available images. Please refer to each one of the source's original publication (referenced in this paper) for details on ethitcal approval.
Funding Statement
This work in its entirety was supported by Transmural Biotech SL.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a study performed using exclusively online and publicly available images from open-source datasets. We were not involved in patient recruitment and/or clinical outcome definition in any way. Therefore no IRB or oversight body was necessary. The downloaded images and their clinical associated info were collected during previous clinical studies, during which individual ethics oversight body were passed. Please refer to each source's website (listed below) and/or publication (referenced in this paper) for more info on the ethical approval of each study.
Of the seven sources used, three were fully open-source and readily available online. The other four required registration to get access to the data. We were granted access in all these four sources by either sending an email to its authors or filling a registration form with our contact information from their website.
Here is the detailed list of sources.
REFUGE. We registered and obtained access through its website: https://refuge.grand-challenge.org/
ODIR. We registered and obtained access through its website: https://odir2019.grand-challenge.org/dataset/
DRISHTI-GS1. We registered and obtained access through its website: https://cvit.iiit.ac.in/projects/mip/drishti-gs/mip-dataset2/Home.php
LAG. We obtained access by sending an email following instructions posted in its website: https://github.com/smilell/AG-CNN
ORIGA. Publicly accessible, no registration required. Downloaded from https://drive.google.com/drive/folders/1VPCvVsPgrfPNIl932xgU3XC_WFLUsXJR
HRF: Publicly accessible, no registration required. https://www5.cs.fau.de/research/data/fundus-images/
SJCHOI86-HRF: Publicly accessible, no registration required. https://github.com/sjchoi86/retina_dataset/tree/master/dataset
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
e-mail: xpburgos{at}transmuralbiotech.com
Data Availability
All used data is fully available since it is from public and open-source online datasets.
